Drugs / CGT6297
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07383506 | Jun 2026 → Jul 2029 expected | endometrial cancer, hormone receptor-positive breast cancer | Cogent Biosciences, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CGT6297 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07383506 ↗ |
| Action | Inhibit | “Mutant-Selective Inhibitor” NCT07383506 ↗ |
| Route | Oral | “CGT6297 Daily Oral Administration” NCT07383506 ↗ |